Sugi Predict

Sugi Predict / Compounds / SCHEMBL214939

SCHEMBL214939

SCHEMBL214939

Cc1ccc(Cl)cc1N(C(=O)c1nc[nH]c1C(N)=O)c1nc2ccccc2[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.36
▸ MAP2 P11137 1/20 0.36
▸ TP53 P04637 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ FPR1 P21462 1/20 0.35
▸ GRM2 Q14416 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRD1 P41143 1/20 0.34
▸ CTDSP1 Q9GZU7 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ KLF5 Q13887 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ JAK2 O60674 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216492 0.91 POLB (0.37) POLBTP53THRBMAPTKMT2A
SCHEMBL215204 0.91 KMT2A (0.37) POLBMAP2MAPTKMT2ANPC1
SCHEMBL214338 0.89 POLB (0.36) POLBMAP2TP53MAPTKMT2A
SCHEMBL215894 0.89 POLB (0.36) POLBMAPTKMT2ANPC1RAB9A
SCHEMBL214715 0.89 POLB (0.40) POLBKMT2ANPC1RAB9ATDP1
SCHEMBL213501 0.89 POLB (0.44) POLBMAP2TP53OPRM1OPRD1
SCHEMBL215085 0.88 GRM2 (0.35) POLBMAP2GRM2MAPTKMT2A
SCHEMBL214140 0.88 POLB (0.48) POLBTP53MAPTKMT2ANPC1
SCHEMBL217227 0.85 POLB (0.37) POLBTP53THRBMAPTKMT2A
SCHEMBL214647 0.85 POLB (0.38) POLBMAPTNPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US claimed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP claimed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885MAP2 730/4885TP53 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.